Considerable pain relief was obtained in the first three postoperative days following the benign anorectal surgery using the newly revised topical formulation comprising Diclofenac and Lidocaine as compared to the Lidocaine alone. This topical approach also provides significantly better results and ease of application as compared to the liposomal Bupivacaine infiltration. 

About 50% of the individuals go through BARS, particularly hemorrhoidectomy, experience mild and severe postoperative pain which could be addressed with a latest CLIFE1 topical approach. This study intended to assess the efficiency and safety of topical Lidocaine plus Diclofenac (CLIFE1) as compared to Lidocaine (CLIFE2) monotherapy in the context of benign anorectal surgery (BARS).

Patients who went through BARS obtained the first dose of either CLIFE1 or CLIFE2 and following each 12 h for the first three postoperative days and once a day from the fourth to sixth. The average pain reduced following the topical treatment was considered as the primary endpoint.

35% of patients of the CLIFE1 group showed significantly reduced postoperative pain as compared to the 18.33 % patients of CLIFE2 group.

Lidocaine plus Diclofenac topical therapy shows greater analgesic efficiency than Lidocaine alone in BARS.